Polaris Pharmaceuticals Inc
Polaris Pharmaceuticals Inc. is a prominent biopharmaceutical company headquartered in San Diego, California, specializing in the development of innovative therapies, notably ADI-PEG 20, a pegylated enzyme targeted at cancer treatment. The company is actively involved in clinical research phases and is pursuing a Biologics License Application (BLA) with the FDA, aiming for approval by 2025.
In addition to its focus on pegargiminase, Polaris Pharmaceuticals collaborates with various partners, including Genovior Biotech Corporation and Bioprofarma, to enhance its research and development capabilities. The company is engaged in a rolling submission process with the FDA, further solidifying its commitment to advancing therapeutic options in the biotechnology field.
Generated from the website